Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2022, and provided business highlights
By Tango Therapeutics, Inc.
Published - Nov 10, 2022, 07:04 AM ET
Last Updated - Mar 27, 2024, 09:19 AM EDT
– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France –
– TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment
of STK11-mutant cancers –
– TNG348 declared as a USP1 inhibitor development candidate for treatment
of BRCA1/2 mutant cancers –
– Aaron Weitzman, M.D., F.A.C.P., appointed Chief Medical Officer –
